GO:0031718 type 1 cannabinoid receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031718 (type 1 cannabinoid receptor binding) is a molecular function defined as binding to a type 1 cannabinoid receptor (CB1).
• CB1 is a G-protein-coupled receptor whose binding interactions are studied with radioligand and fluorescent probes.
• CB1 binding is quantified in native tissue using radioligand assays and PET imaging.
• CB1 receptor densities vary across species and social organization, reflecting biological diversity.
• CB1 regulates growth cone filopodia and axon dispersion during neural development.
• A cryptic pocket in CB1 can drive peripheral and functional selectivity of binding.
Description
GO:0031718, type 1 cannabinoid receptor binding, is a molecular function term in the Gene Ontology that describes the binding of a molecule to a type 1 cannabinoid receptor (CB1). CB1 is a G-protein-coupled receptor that mediates the effects of endocannabinoids and exogenous cannabinoids, and its binding properties are central to understanding cannabinoid signaling in the nervous system and beyond. Researchers study this function to characterize ligand-receptor interactions, receptor distribution, and the pharmacological selectivity of CB1-targeting compounds. The term is distinct from receptor activation or downstream signaling; it specifically captures the physical interaction between a ligand and CB1. Because CB1 is implicated in diverse physiological processes, from neural development to motor control, assays that measure type 1 cannabinoid receptor binding are essential tools in neurobiology and drug discovery. This article summarizes the authoritative definition, the molecular and cellular context, key genes and proteins, disease relevance, and the experimental methods used to investigate GO:0031718.
type 1 cannabinoid receptor binding At A Glance
| GO ID | GO:0031718 |
|---|---|
| GO term | type 1 cannabinoid receptor binding |
| Ontology | molecular_function |
| Synonym | type 1 cannabinoid receptor ligand |
| Major function | Binding to a type 1 cannabinoid receptor (CB1) |
| Receptor family | G-protein-coupled receptor (CB1) |
| Common assay | Radioligand binding assay |
| Related probe | Fluorescent CB1 probes |
| Tissue context | Nervous system and peripheral tissues |
What Is GO:0031718?
Type 1 cannabinoid receptor binding (GO:0031718) is the molecular function of selectively interacting with a type 1 cannabinoid receptor (CB1). It is defined by the Gene Ontology as binding to a type 1 cannabinoid receptor, and the synonym type 1 cannabinoid receptor ligand reflects the ligand-side perspective of this interaction. This function is measured experimentally by detecting the association of a labeled or unlabeled ligand with CB1, often using radioligand binding assays or fluorescent probes.
Why Is type 1 cannabinoid receptor binding Important in Cell Biology?
Type 1 cannabinoid receptor binding is important because CB1 is a major modulator of synaptic transmission and neural development, and its binding properties determine how endogenous and exogenous cannabinoids exert their effects. Quantifying this binding in native tissues and in vivo provides insight into receptor density, ligand selectivity, and functional outcomes relevant to neurological and psychiatric conditions.
• CB1 binding is the first step in cannabinoid signaling and is required for receptor-mediated effects.
• Radioligand binding assays enable quantitative measurement of CB1 affinity and density.
• PET imaging with CB1-selective radiotracers allows in vivo assessment of receptor availability.
• CB1 binding densities differ across species and social systems, informing comparative neurobiology.
• CB1 regulates growth cone filopodia and axon dispersion in developing visual pathways.
• Selective fluorescent probes for CB1 facilitate visualization of receptor binding in cells.
• A cryptic pocket in CB1 can be targeted to achieve peripheral and functional selectivity.
• CB1 binding is relevant to Parkinson's disease and other neurodegenerative conditions.
• Understanding CB1 binding supports development of therapeutics with improved selectivity.
• The CB1 carboxyl-terminus contributes to receptor interactions beyond the binding pocket.
Molecular Mechanism of type 1 cannabinoid receptor binding
Ligand recognition by CB1
In simple terms: A ligand fits into a specific pocket on the CB1 receptor, like a key in a lock.
Type 1 cannabinoid receptor binding begins with recognition of a ligand by the CB1 receptor, a G-protein-coupled receptor. Radioligand binding assays are used to measure this interaction, typically by incubating CB1-containing membranes with a labeled ligand and determining specific binding. The binding event is saturable and reversible, consistent with a receptor-ligand interaction.
Radioligand binding assay principles
In simple terms: Scientists use radioactive or fluorescent tags to see how strongly a molecule sticks to CB1.
The assay of CB1 receptor binding involves incubating a radiolabeled ligand with CB1-expressing membranes or cells, separating bound from free ligand, and quantifying the bound fraction. This approach allows determination of affinity (Kd) and receptor density (Bmax). The method is foundational for characterizing type 1 cannabinoid receptor binding in vitro.
Fluorescent probe binding
In simple terms: Special glowing molecules can light up CB1 so researchers can watch binding in living cells.
Highly selective drug-derived fluorescent probes for CB1 have been developed to study receptor binding and localization. These probes enable real-time visualization of type 1 cannabinoid receptor binding in cellular contexts and can complement radioligand assays.
Allosteric and cryptic pocket modulation
In simple terms: Some molecules bind to hidden pockets on CB1 to change how the receptor works.
A cryptic pocket in CB1 has been identified that drives peripheral and functional selectivity, expanding the understanding of type 1 cannabinoid receptor binding beyond the orthosteric site. This finding suggests that binding at alternative sites can modulate receptor function in a tissue-selective manner.
Receptor carboxyl-terminus contributions
In simple terms: The tail of the CB1 receptor helps it interact with other proteins, not just ligands.
The carboxyl-terminus of CB1 is more than a passive tail; it contributes to receptor interactions and regulation. While the binding pocket is the primary site for type 1 cannabinoid receptor binding, the carboxyl-terminus influences receptor trafficking and coupling.
Key Genes Involved in GO:0031718 type 1 cannabinoid receptor binding
The following genes and proteins are central to type 1 cannabinoid receptor binding and its study.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CNR1 | Encodes the type 1 cannabinoid receptor (CB1) | Primary receptor for GO:0031718 binding assays |
| CNR2 | Encodes the type 2 cannabinoid receptor (CB2) | Related receptor for comparative binding studies |
| GNAI1 | G-protein alpha subunit coupled to CB1 | Downstream signaling after binding |
| GNAI2 | G-protein alpha subunit coupled to CB1 | Downstream signaling after binding |
| GNAI3 | G-protein alpha subunit coupled to CB1 | Downstream signaling after binding |
| GNAO1 | G-protein alpha subunit coupled to CB1 | Downstream signaling after binding |
| ARRB1 | Beta-arrestin 1 involved in CB1 desensitization | Regulation of receptor after binding |
| ARRB2 | Beta-arrestin 2 involved in CB1 desensitization | Regulation of receptor after binding |
| DAGLA | Diacylglycerol lipase alpha, endocannabinoid synthesis | Endogenous ligand production |
| DAGLB | Diacylglycerol lipase beta, endocannabinoid synthesis | Endogenous ligand production |
| NAPE-PLD | N-acyl phosphatidylethanolamine phospholipase D | Endocannabinoid synthesis |
| FAAH | Fatty acid amide hydrolase, degrades endocannabinoids | Ligand availability |
| MGLL | Monoacylglycerol lipase, degrades 2-AG | Ligand availability |
| CNR1 (CB1) in Microtus | Receptor densities reflect social organization | Comparative neurobiology |
| CNR1 in Parkinson's disease | Receptor availability measured by PET | Neurodegeneration |
| CB1 in Xenopus laevis | Regulates growth cone filopodia and axon dispersion | Developmental neuroscience |
| CB1 cryptic pocket | Drives peripheral and functional selectivity | Drug discovery |
| CB1 fluorescent probes | Visualize receptor binding | Chemical biology |
How Is type 1 cannabinoid receptor binding Regulated?
Type 1 cannabinoid receptor binding is regulated at multiple levels. Receptor desensitization and internalization following agonist binding involve beta-arrestins and the carboxyl-terminus of CB1. The availability of endogenous ligands is controlled by synthesis and degradation enzymes such as DAGLA, NAPE-PLD, FAAH, and MGLL. Additionally, allosteric modulation via a cryptic pocket can alter binding selectivity and functional outcomes.
type 1 cannabinoid receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CNR1 | Parkinson's disease | PET imaging with [18F]FMPEP-d2 |
| CNR1 | Neural development | Xenopus laevis optic tract |
| CNR1 | Social behavior | Microtus species comparison |
| CNR1 | Cannabinoid signaling | Radioligand binding assays |
| CNR1 | Drug selectivity | Fluorescent probe binding |
Parkinson's disease
Cannabinoid receptor type 1 availability has been studied in Parkinson's disease using positron emission tomography with [18F]FMPEP-d2, revealing changes in receptor binding in patients. This suggests that type 1 cannabinoid receptor binding is relevant to the pathophysiology and potential treatment of Parkinson's disease.
Neurodevelopmental disorders
CB1 regulates growth cone filopodia and axon dispersion in the optic tract of Xenopus laevis tadpoles, indicating a role for type 1 cannabinoid receptor binding in neural development. Disruption of this function could contribute to developmental disorders.
Neuropsychiatric and social behavior
Cannabinoid receptor type 1 densities reflect social organization in Microtus, linking type 1 cannabinoid receptor binding to social behavior and potentially to neuropsychiatric conditions.
From type 1 cannabinoid receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CNR1 knockout alter CB1 binding? | CNR1 knockout cell line or animal |
| Does a point mutation in CNR1 change ligand affinity? | Point-mutation knock-in of CNR1 |
| Can a tagged CB1 be used to visualize binding? | Tagged knock-in of CNR1 |
| Does overexpression of CNR1 increase binding sites? | CNR1 overexpression cell line |
| Can CRISPR library screening identify modifiers of CB1 binding? | CRISPR library screening in CB1-expressing cells |
| Does a cryptic pocket mutation affect selectivity? | Point-mutation knock-in at cryptic pocket residues |
How to Study the type 1 cannabinoid receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Affinity and receptor density | In vitro characterization of CB1 ligands |
| Fluorescent probe binding | Receptor localization and binding dynamics | Live-cell imaging |
| PET imaging | In vivo receptor availability | Clinical and preclinical studies |
| Autoradiography | Regional receptor density | Brain mapping |
| Functional assays | Downstream signaling after binding | G-protein activation |
| CRISPR knockout | Loss of receptor function | Target validation |
| CRISPR knock-in | Mutant receptor binding properties | Structure-function studies |
Radioligand binding assay
The radioligand binding assay is the classic method to measure type 1 cannabinoid receptor binding. It involves incubating CB1-containing membranes with a radiolabeled ligand, separating bound from free ligand, and quantifying specific binding to determine affinity and receptor density.
Fluorescent probe imaging
Highly selective fluorescent probes for CB1 enable visualization of type 1 cannabinoid receptor binding in live cells and tissues, allowing spatial and temporal resolution of receptor-ligand interactions.
Positron emission tomography (PET)
PET imaging with CB1-selective radiotracers such as [18F]FMPEP-d2 allows non-invasive measurement of type 1 cannabinoid receptor binding in vivo, as demonstrated in Parkinson's disease studies.
Comparative receptor autoradiography
Receptor autoradiography using radioligands can map CB1 densities across brain regions and species, revealing differences that reflect social organization and behavior.
How CRISPR Can Be Used to Study GO:0031718 type 1 cannabinoid receptor binding
Knockout
CRISPR knockout of CNR1 can eliminate type 1 cannabinoid receptor binding, providing a clean background to study ligand specificity and downstream effects. Knockout models are useful for validating that observed binding is CB1-specific.
Point Mutation
Point mutations in CNR1 can be introduced to probe the binding pocket or cryptic pocket residues, revealing how specific amino acids contribute to type 1 cannabinoid receptor binding and selectivity.
Knock-in
Knock-in of tagged or reporter versions of CNR1 allows visualization and quantification of type 1 cannabinoid receptor binding in native contexts, facilitating imaging and biochemical studies.
Overexpression
Overexpression of CNR1 in cell lines increases the number of binding sites, enabling robust radioligand binding assays and high-throughput screening for CB1 ligands.
How EDITGENE Supports type 1 cannabinoid receptor binding Research
Researchers studying type 1 cannabinoid receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, ligand affinity, or downstream signaling. EDITGENE provides comprehensive CRISPR-based services to create precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for type 1 cannabinoid receptor binding research.
Frequently Asked Questions About type 1 cannabinoid receptor binding
What is type 1 cannabinoid receptor binding?
Type 1 cannabinoid receptor binding (GO:0031718) is the molecular function of binding to a type 1 cannabinoid receptor (CB1), as defined by the Gene Ontology.
What genes are involved in type 1 cannabinoid receptor binding?
The primary gene is CNR1, which encodes the CB1 receptor. Other related genes include CNR2, GNAI1, GNAI2, GNAI3, GNAO1, ARRB1, ARRB2, DAGLA, DAGLB, NAPE-PLD, FAAH, and MGLL.
How is type 1 cannabinoid receptor binding measured?
It is commonly measured using radioligand binding assays, fluorescent probes, and PET imaging with CB1-selective radiotracers.
What is the role of CB1 in the brain?
CB1 is a G-protein-coupled receptor that modulates synaptic transmission and neural development, including regulation of growth cone filopodia and axon dispersion.
Is type 1 cannabinoid receptor binding involved in Parkinson's disease?
Yes, PET studies with [18F]FMPEP-d2 have shown altered CB1 availability in Parkinson's disease patients.
What is a cryptic pocket in CB1?
A cryptic pocket in CB1 is an alternative binding site that can drive peripheral and functional selectivity of ligands.
Can CRISPR be used to study type 1 cannabinoid receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the function and binding properties of CB1.
What are the synonyms for type 1 cannabinoid receptor binding?
The synonym is type 1 cannabinoid receptor ligand, reflecting the ligand perspective of the binding interaction.
How does CB1 binding differ across species?
CB1 receptor densities reflect social organization in Microtus species, indicating species-specific differences in type 1 cannabinoid receptor binding.
What is the carboxyl-terminus of CB1?
The carboxyl-terminus of CB1 is more than just a tail; it contributes to receptor interactions and regulation beyond the binding pocket.
Conclusion
Type 1 cannabinoid receptor binding (GO:0031718) is a fundamental molecular function that underlies cannabinoid signaling. Its study spans radioligand assays, fluorescent probes, PET imaging, and CRISPR-based models, with relevance to Parkinson's disease, neural development, and social behavior. Understanding this binding function is essential for developing selective therapeutics targeting CB1.
References
- 1. Gasperi V et al.. 2023. Assay of CB(1) Receptor Binding.. Methods Mol Biol 2576:95-109 PMID: 36152179
- 2. Simmons TC et al.. 2021. Cannabinoid receptor Type 1 densities reflect social organization in Microtus.. J Comp Neurol 529(5):1004-1017 PMID: 33460115
- 3. Ajalin RM et al.. 2022. Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [(18) F]FMPEP-d(2).. Mov Disord 37(8):1673-1682 PMID: 35674270
- 4. Stadel R et al.. 2011. The cannabinoid type-1 receptor carboxyl-terminus, more than just a tail.. J Neurochem 117(1):1-18 PMID: 21244428
- 5. Rangari VA et al.. 2025. A cryptic pocket in CB1 drives peripheral and functional selectivity.. Nature 640(8057):265-273 PMID: 40044849
- 6. Elul T et al.. 2022. Cannabinoid Receptor Type 1 regulates growth cone filopodia and axon dispersion in the optic tract of Xenopus laevis tadpoles.. Eur J Neurosci 55(4):989-1001 PMID: 35060216
- 7. Paudel P et al.. 2023. Cannabinoid Receptor Type II Ligands from Sandalwood Oil and Synthetic α-Santalol Derivatives.. J Nat Prod 86(7):1786-1792 PMID: 37450763
- 8. Mach L et al.. 2024. Highly Selective Drug-Derived Fluorescent Probes for the Cannabinoid Receptor Type 1 (CB(1)R).. J Med Chem 67(14):11841-11867 PMID: 38990855
